KR102260163B1 - Antimicrobial Cosmetic Composition - Google Patents

Abstract

hydroxyacetophenone or a salt thereof; And it relates to an antibacterial composition comprising a capryl hydroxamic acid or a salt thereof.

Description

Antimicrobial Cosmetic Composition

It relates to an antibacterial composition comprising hydroxyacetophenone (Hydroxyacetophenone) and caprylhydroxamic acid (Caprylhydroxamic acid).

Many products such as food, medicine, daily necessities, and cosmetics widely used in our daily life contain preservatives, which are antibacterial substances approved for human use to prevent changes in internal properties and preserve them for a certain period of time. In particular, 　 cosmetics can be used by hand or because of the nature of products that come in frequent contact with the human body, microorganisms can be introduced from the outside, and the quality of products can be changed by these microorganisms. Accordingly, the use of substances that prevent the proliferation of microorganisms in cosmetics is essential to ensure product quality and consumer safety. Accordingly, a number of antibacterial active compounds are used in cosmetics (Republic of Korea Patent Publication No. 10-1962266).

However, using one type of antibacterial agent causes a problem in that bacteria resistant to the antibacterial agent appear, and it is difficult to kill the generated resistant bacteria, and there is a risk of proliferation in other various products. In addition, when one type of antibacterial agent is used in a high content, it may affect the stability of cosmetics. Therefore, while minimizing the amount of the antimicrobial agent, research on a combination of antimicrobial substances is required to broaden the range of microorganisms exhibiting antimicrobial activity.

Under this background, the present inventors confirmed that the combination of hydroxyacetophenone and capryl hydroxamic acid exhibits a synergistic effect of antimicrobial activity against microorganisms.

One aspect is hydroxyacetophenone or a salt thereof; And it provides an antibacterial composition comprising a capryl hydroxamic acid or a salt thereof.

Another aspect is hydroxyacetophenone or a salt thereof; And it provides a cosmetic composition comprising an antibacterial composition comprising capryl hydroxamic acid or a salt thereof.

Another aspect is hydroxyacetophenone or a salt thereof; And it provides a composition for external application to the skin comprising an antibacterial composition comprising capryl hydroxamic acid or a salt thereof.

Another aspect is hydroxyacetophenone or a salt thereof; And it provides a pharmaceutical composition comprising an antibacterial composition comprising a capryl hydroxamic acid or a salt thereof.

One aspect is hydroxyacetophenone or a salt thereof; And it provides an antibacterial composition comprising a capryl hydroxamic acid or a salt thereof.

the hydroxyacetophenone or a salt thereof; and the weight ratio of caprylhydroxamic acid or salt thereof is from 4:1 to 1:16, for example from 4:1 to 1:12, for example from 4:1 to 1:8, for example. For example, 4:1 to 1:4, such as 4:1 to 1:2, such as 4:1 to 1:1, such as 1:1 to 1:16, such as, 1:2 to 1:16, for example, 1:4 to 1:16 may be included. In one embodiment, when the weight ratio of the hydroxyacetophenone and capryl hydroxamic acid is 4:1 to 1:16, synergistic effect in antibacterial activity compared to when each material is used alone It was confirmed that the Therefore, when out of the above range, the synergistic effect of the combination of hydroxyacetophenone and capryl hydroxamic acid may be insignificant.

The composition comprises 0.1% to 0.6% by weight of hydroxyacetophenone or a salt thereof, such as 0.15% to 0.6% by weight, such as 0.2% to 0.6% by weight, such as 0.25% by weight. to 0.6 wt%, for example, 0.25 wt% to 0.55 wt% may be included. When out of the above range, if the content of hydroxyacetophenone is too small, antibacterial activity may not be exhibited, or if the content of hydroxyacetophenone is too high, the formulation stability of the composition may be negatively affected.

The composition comprises 0.05% to 0.6% by weight of caprylhydroxamic acid or a salt thereof, for example 0.75% to 0.6% by weight, for example 0.1% to 0.6% by weight, for example 0.125 Weight% to 0.6% by weight, for example, it may be included in 0.125% by weight to 0.55% by weight. When out of the above range, if the content of capryl hydroxamic acid is too small, antibacterial activity may not be exhibited, or if the content of capryl hydroxamic acid is too high, the formulation stability of the composition may be negatively affected.

The cosmetic composition may include hydroxyacetophenone or a salt thereof; And capryl hydroxamic acid or a salt thereof may be appropriately included in combination to exhibit a remarkable synergistic effect in antibacterial activity compared to the use of a single substance, and may maintain formulation stability of the composition.

The antibacterial composition may be added to a cosmetic composition, an antiseptic composition, a pharmaceutical composition, and a quasi-drug composition for antibacterial properties.

As used herein, the term “antibacterial” refers to the ability to resist the growth of microorganisms, and refers to all mechanisms made to defend against physical and chemical actions that may occur during the growth of microorganisms such as bacteria, mold, yeast, and the like.

As used herein, the term "antibacterial composition" may refer to an antiseptic composition, and may include all additives that can be used to prevent deterioration, decay, discoloration and chemical change of the composition to which they are added. For example, food preservatives, cosmetic preservatives, pharmaceutical preservatives, disinfectants, antioxidants, etc. may be included, and inhibit the growth of microorganisms such as bacteria, mold, yeast, etc. to inhibit the growth of spoilage microorganisms in food, cosmetics, and pharmaceuticals. Functional antibiotics such as bactericidal action may also be included.

The term "bacteria" refers to prokaryotes, the most prosperous species of living organisms, among which are pathogenic bacteria. The size varies from 0.5 μm to 0.5 mm. The bacteria include, for example, Staphylococcus aureus (Staphylococcusaureus), E. coli, including, (Escherichia coli), Pseudomonas aeruginosa (Paeudomonas aeruginosa), but is not limited thereto. The term, "fungi" refers to a group of microorganisms composed of more than 72,000 species, including mold and yeast, and belongs to eukaryotes with a nuclear membrane, and organelles such as mitochondria and endoplasmic reticulum are developed, chitin, glucan, etc. It has a cell wall composed of Most fungi form cellular mycelium to elongate, develop, and form spores as propagules, but some fungal species proliferate unicellularly. It is mainly involved in organic decomposition in nature as saprophytes, but some are parasitic or symbiotic with animals and plants. The fungi include, for example, heukgukgyun ( Aspergillus niger ), blue mold genus ( Penicillium sp.), but is not limited thereto. As used herein, the term “yeast” refers to a single-celled organism that has no hyphae and does not have photosynthetic or motility, and is known to have a cell cycle similar to that of a human cell cycle as the simplest type of eukaryote. The yeast includes, for example, Saccharomyces sp., Pichia sp., and Candida sp., but is not limited thereto.

The composition exhibits antibacterial activity against one or more microorganisms selected from the group consisting of Escherichia coli , Pseudomonas aeruginosa , Staphylococcus aureus , Candida albicans ) and Aspergillus niger. can In one embodiment, it was confirmed that the antibacterial composition exhibits a synergistic effect of antibacterial activity against E. coli and Staphylococcus aureus.

Another aspect is hydroxyacetophenone or a salt thereof; And it provides a cosmetic composition comprising an antibacterial composition comprising capryl hydroxamic acid or a salt thereof. The hydroxyacetophenone, capryl hydroxamic acid, antibacterial and the like are the same as described above.

The cosmetic composition may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil , powder foundation, emulsion foundation, wax foundation and spray, etc., but are not limited thereto. More specifically, it may be prepared in the form of soft lotion, nourishing lotion, cream, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the formulation of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide is used as a carrier component. can be

When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propellants such as propane/butane or dimethyl ether.

When the formulation of the cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan may be used.

When the formulation of the cosmetic composition is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.

In the case of surfactant-containing cleansing of the cosmetic composition, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether as carrier components Sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester may be used.

The cosmetic composition may further add components such as a dispersant, an antioxidant, a preservative, a pH adjuster, a humectant, and a lubricant, if necessary. In addition, the color cosmetic 　 composition further includes a substance that can supplementally provide essential nutrients to the skin, and preferably contains an auxiliary agent including but not limited to natural fragrance, cosmetic fragrance, or plant extract. have.

Another aspect is hydroxyacetophenone or a salt thereof; And it provides a composition for external application to the skin comprising an antibacterial composition comprising capryl hydroxamic acid or a salt thereof. The hydroxyacetophenone, capryl hydroxamic acid, antibacterial and the like are the same as described above.

In this specification, the term "skin 　 external use" is a concept that encompasses the overall composition used for external use, and various pharmaceuticals such as cosmetic compositions or ointments, including various cosmetics such as basic cosmetics, makeup cosmetics, hair cosmetics, and shaving cosmetics. It may mean that it can be widely applied to quasi-drugs and the like. For example, the quasi-drug may be a disinfectant cleaner, shower foam, gargrin, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment, coating agent, or filter filler.

In addition to the active ingredients, the skin 　 composition for external use is a component that is usually formulated for 　 external use depending on the intended use and the nature of the 　 external preparation, specifically moisturizing agents, ultraviolet absorbers, vitamins, animal and plant extracts, digestive agents, whitening agents, vasodilators, astringents, and refreshing agents. , a hormone agent, etc. may be additionally formulated.

The formulation of the skin 　 external composition may take an appropriate form depending on the intended use and the 　 external application 　 composition, specifically, an aqueous solution, solubilization, emulsification, emulsion, gel, paste, ointment, aerosol, water- It may be an oil two-layer system or a water-oil-powder three-layer system, and the formulation and form of the external preparation of the present invention are not limited by the formulation.

In addition, the 　 skin 　 external preparation may further include a base necessary for penetrating or transferring the active ingredient 　 into the skin tissue.

Another aspect is hydroxyacetophenone or a salt thereof; And it provides a pharmaceutical composition comprising an antibacterial composition comprising a capryl hydroxamic acid or a salt thereof. The hydroxyacetophenone, capryl hydroxamic acid, antibacterial and the like are the same as described above.

The 　antibacterial composition may be included as an active ingredient of a 　pharmaceutical composition having antibacterial activity, or it may be used as an adjuvant of an active ingredient having a pharmaceutical use. The 　pharmaceutical composition can be prepared according to a method well known to those skilled in the art.

The above 　 pharmaceutical composition can be formulated in the form of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions or syrups, oral dosage forms, external preparations, suppositories, or injection solutions according to conventional methods. In detail, when formulating, it may be prepared using a diluent or excipient such as a filler, a weight agent, a binder, a wetting agent, a disintegrant, and a surfactant commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. in addition to the composition containing ethylhexyl gallate. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It can be prepared by adding various excipients, for example, wetting agents, sweetening agents, fragrances, preservatives, etc. in addition to liquids for oral use and liquid paraffin. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, Witepsol, Macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, etc. may be used.

The pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may vary depending on the condition and weight of the patient, the degree of disease, the drug Although it varies depending on the form, administration route and time, it may be appropriately selected by those skilled in the art.

Another aspect provides a 　 antibacterial 　 method comprising the step of treating the antibacterial composition to the bacteria.

The hydroxyacetophenone, capryl hydroxamic acid, antibacterial and the like are the same as described above.

The 　 method of treating the antibacterial composition to the bacteria 　 can be appropriately used according to a conventional method well known to those skilled in the art in various fields requiring antibacterial. The treatment amount of the antimicrobial composition may be appropriately determined depending on the intended use.

Antibacterial composition according to an aspect may exhibit a synergistic effect in antibacterial activity by combining hydroxyacetophenone and caprylhydroxamic acid in a suitable ratio. Therefore, when they are included in the cosmetic composition, it is possible to secure the stability and safety of the formulation by minimizing the amount of the antibacterial agent.

1 is a view showing a method for confirming the antibacterial synergistic effect against E. coli (Escherichia coli ATCC 8739) and Staphylococcus aureus ATCC 6538 according to the combination ratio of hydroxyacetophenone and caprylic acid.
Figure 2 is a view showing the degree of discoloration of the cosmetic composition (shampoo) containing hydroxyacetophenone 0.6% by weight.
3 is a view showing the degree of discoloration of the cosmetic composition (essence) containing hydroxyacetophenone 0.6% by weight.
Figure 4 is a view showing the degree of discoloration of the cosmetic composition (foam cleanser) containing hydroxyacetophenone 0.6% by weight.
Figure 5 is a view showing the degree of discoloration of the cosmetic composition (lotion) containing hydroxyacetophenone 0.6% by weight.
6 is a view showing the degree of discoloration of the cosmetic composition (skin) containing hydroxyacetophenone 0.6% by weight.

Hereinafter, it will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example 1. Confirmation of the minimum concentration exhibiting antibacterial activity

Since the use of a high content of antibacterial agents may have a negative effect on the stability and safety of the cosmetic composition, the antibacterial activity of hydroxyacetophenone (HAP) and caprylhydroxamic acid (CHA) is reduced. It was attempted to confirm the minimum concentration indicated.

Specifically, E. coli ( E. coli ) And Staphylococcus aureus ( S. aureus ) was smeared on tryptic soy agar (TSA), and cultured at 32 ° C. for 24 hours to obtain uncontaminated pure colonies. A colony of each purely isolated bacteria was inoculated into TSA, incubated at 32° C. for 24 hours, and a bacterial solution reaching the exponential phase was prepared. The prepared bacterial solution was serially diluted with 0.85% NaCl solution, and plated on TSA. After incubating the plate with the bacteria at 32 °C for 24 hours, the number of colonies is multiplied by the dilution factor to check the final number of bacteria in the bacterial solution. TSA was added to the bacterial solution for which the number of bacteria was confirmed, and the final number of bacteria was diluted not to exceed ^{10 6 CFU/ml.} At this time, raw materials and extracts having high water solubility were diluted with TSA, and in the case of raw materials having low water solubility, 0.01% of lecithin was added to TSA, and then the raw materials were diluted while heating in a bath. 100 μl of the bacterial solution adjusted to the number of bacteria was put into 3 compartments in each row of a 96-well plate. Put 100 μl of the prepared raw material into the 3 columns of the first row of the plate containing 100 μl of the bacterial solution, mix the bacteria and the raw material well, then add 100 μl to the 3 rows of the next row, and add the raw material to row 1 It was diluted to 1/2 of the concentration. In this way, the raw material was diluted by 1/2 stepwise.

The 96-well plate in which the strain and the diluted sample were dispensed was cultured in an incubator at 32° C. for 24 hours, and then, by checking the suspension level of the medium, the proliferation of the bacteria was visually determined. Since the same strain was contained in three columns of each row of the plate, the suspension levels of the three columns were observed together. As a result of observing the suspension, the lowest concentration among the concentrations in which the bacteria did not grow was determined as the minimum inhibitory concentration (MIC: Minimal Inhibitory Concentration) value of the raw material.

strain hydroxyacetophenone capryl hydroxamic acid E. coli 0.25% by weight 0.125 wt% S. aureus 0.25% by weight 0.125 wt%

As a result, as shown in Table 1 above, in the case of hydroxyacetophenone, the minimum concentration showing antibacterial activity against E. coli and Staphylococcus aureus is 0.25 wt %, and in the case of capryl hydroxamic acid, the two types of It was confirmed that the minimum concentration showing antibacterial activity against bacteria was 0.125 wt%.

Example 2. Confirmation of antibacterial synergistic effect according to the combination of hydroxyacetophenone and capryl hydroxamic acid

It was attempted to confirm the antibacterial synergistic effect according to the weight ratio of the combination of hydroxyacetophenone and capryl hydroxamic acid.

Specifically, E. coli ( E. coli ) And Staphylococcus aureus ( S. aureus ) was plated on tryptic soy broth (TSB), and cultured at 32 ° C. for 24 hours to obtain uncontaminated pure colonies. A colony of each purely isolated bacteria was inoculated into TSB, incubated at 32 °C for 24 hours, and a bacterial solution reaching the exponential phase was prepared. The prepared bacterial solution was diluted using TSB so that the final number of bacteria ^{did not exceed 10 6} CFU/ml, and then 50 μl was dispensed into each well of a 96-well plate. At this time, the raw material and extract are diluted with TSB if the solubility in water is high. Raw materials with low solubility in water were diluted while heating in a bath after adding 0.01% of lecithin to TSB.

The experimental method for confirming the antibacterial synergistic effect of hydroxyacetophenone and capryl hydroxamic acid is shown in FIG. 1 . Specifically, hydroxyacetophenone and capryl hydroxamic acid to confirm the antibacterial synergistic effect were diluted to 8 times the minimum inhibitory concentration (MIC) confirmed in Example 1, respectively. By diluting the raw material prepared by using TSB by 1/2 stepwise, a raw material diluted from 8 times to 1/16 times the minimum inhibitory concentration was prepared. In each row and column of a 96-well plate, hydroxyacetophenone and caprylhydroxamic acid, respectively, were added to each well in order from low (1/16 times the minimum inhibitory concentration) to high concentrations (8 times the minimum inhibitory concentration). 25 μl each was dispensed. No bacteria was added to the negative control wells, 100 μl of hydroxyacetophenone and capryl hydroxamic acid were dispensed, and 100 μl of only the strain was dispensed into the positive control wells.

The 96-well plate in which the strain and the diluted sample were dispensed was cultured in an incubator at 32 ° C. for 24 hours, and then the mixing ratio of the minimum concentration at which the growth of the bacteria was not observed with the naked eye was confirmed. The fractional inhibiting concentration (FIC) and FIC index (FIC index) were calculated by substituting the result of the most efficiently combined concentration into the following formula.

- FIC of HAP or CHA = (MIC of HAP or CHA in combination) / (MIC when using HAP or CHA alone)

- FIC Index = HAP FIC + CHA FIC

At this time, if the calculated FIC index ≤ 0.5, a synergistic effect; 0.5<FIC index ≤1, partial synergistic effect; If 1<FIC index ≤4, it is irrelevant; If the FIC index>4, it is determined that there is an antagonistic effect.

strain result HAP: CHA FIC Index E. coli partial synergy 1:16 0.5156 1:8 0.5312 1: 4 0.5625 1: 2 0.625 1:1 0.75 irrelevant 1:32 1.0156 Staphylococcus aureus (S. aureus) partial
synergy 4:1 0.75 1:1 0.75 irrelevant 8:1 1.25

As a result, as shown in Table 2 above, when the weight ratio of hydroxyacetophenone and capryl hydroxamic acid is included in a ratio of 1:1 to 1:16, it exhibits a partial synergistic effect in antibacterial activity against E. coli. was confirmed. On the other hand, when the weight ratio of hydroxyacetophenone and capryl hydroxamic acid was included at 1:32, it was confirmed that there was no synergistic effect in antibacterial activity against E. coli.

In addition, when the weight ratio of hydroxyacetophenone and capryl hydroxamic acid was included in a range of 4:1 to 1:1, it was confirmed that a partial synergistic effect was exhibited in antibacterial activity against Staphylococcus aureus. On the other hand, when the weight ratio of hydroxyacetophenone and capryl hydroxamic acid was 8:1, it was confirmed that there was no synergistic effect in the antibacterial activity against Staphylococcus aureus.

In summary, when the weight ratio of hydroxyacetophenone and capryl hydroxamic acid is included in a ratio of 4:1 to 1:16, it is confirmed that the antibacterial activity is significantly increased compared to the case where each material is used alone. did.

Example 3. Confirmation of the maximum concentration that does not affect the formulation stability of the cosmetic composition

Since the high content of the antimicrobial agent may have a negative effect on the formulation stability of the cosmetic composition, the maximum concentration that does not affect the stability of the formulation was identified.

Specifically, shampoos, essences, foam cleansers, lotions, and skins that do not contain hydroxyacetophenone were prepared. Five formulations were selected to compare the degree of discoloration due to hydroxyacetophenone in each formulation. Hydroxyacetophenone was diluted by 60% by using propanediol to increase the solubility of the diluted raw material and to be uniformly mixed into the formulation. Diluted hydroxyacetophenone was added at 1/100 of the mass of the formulation, so that each formulation finally contained 0.6% by weight of hydroxyacetophenone. A sample not containing hydroxyacetophenone and one sample containing 0.6% by weight of hydroxyacetophenone were stored in a thermostat that blocks light and a window that can be exposed to light, respectively. After one month of storage, the samples were compared for discoloration.

formulation Without hydroxyacetophenone Contains 0.6% by weight of hydroxyacetophenone thermostat window thermostat window shampoo no discoloration no discoloration no discoloration discolored essence no discoloration no discoloration no discoloration Discoloration and turbidity of the sample foam cleanser no discoloration no discoloration no discoloration discolored Lotion no discoloration no discoloration no discoloration discolored skin no discoloration no discoloration no discoloration Discoloration and turbidity of the sample

As a result, as shown in Table 3, when stored in a light-blocked state, no discoloration occurred in all formulations of the cosmetic composition, regardless of whether hydroxyacetophenone was included. On the other hand, when stored in a state in which light is not blocked, it was confirmed that discoloration occurred in the cosmetic composition containing hydroxyacetophenone in an amount of 0.6 wt%, compared to the cosmetic composition not containing hydroxyacetophenone.

Through the above results, it was confirmed that when hydroxyacetophenone is included in an amount of 0.6 wt % or more, it can cause discoloration of the cosmetic composition, which can negatively affect the stability of the formulation.

From the above results, it was confirmed that the antibacterial composition can exhibit a synergistic effect in antibacterial activity by appropriately mixing and including hydroxyacetophenone and capryl hydroxamic acid.

In addition, the minimum concentrations exhibiting antibacterial activity of hydroxyacetophenone and caprylhydroxamic acid are 0.25% by weight and 0.125% by weight, respectively; It was confirmed that the range that does not negatively affect the stability of the cosmetic composition formulation is 0.6% by weight or less.

Claims (8)

Hydroxyacetophenone or a salt thereof; And capryl hydroxamic acid (Caprylhydroxamic acid) or a salt thereof as an antibacterial composition comprising a mixed weight ratio of 1:4 to 1:16,
the hydroxyacetophenone or a salt thereof; And the combination of the capryl hydroxamic acid or a salt thereof is E. coli (Escherichia coli), Staphylococcus aureus (Staphylococcus aureus), or a composition that exhibits a synergistic effect of antibacterial activity against a combination thereof.
delete The method according to claim 1, comprising 0.2 wt% to 0.6 wt% of the hydroxyacetophenone or a salt thereof; The composition comprising the capryl hydroxamic acid or its salt in an amount of 0.1 wt% to 0.6 wt%.
delete A cosmetic composition comprising the antibacterial composition of claim 1 or 3.
6. The group of claim 5, wherein the composition comprises solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing agents, oils, powder foundations, emulsion foundations, wax foundations, and sprays. One or more formulations selected from the cosmetic composition.
A composition for external application to the skin comprising the antibacterial composition of claim 1 or 3.
An antibacterial pharmaceutical composition comprising the antimicrobial composition of claim 1 or 3.

Images